CSL Vifor and Travere Therapeutics announced that the European Commission has granted conditional marketing authorization, or CMA, for Filspari for the treatment of adults with primary IgAN with a urine protein excretion of 1.0 g/day. The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space
- Travere Therapeutics downgraded to Neutral from Buy at Guggenheim
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
